An inspection of the firm’s Ladenburg, Germany site by the US Food and Drug Administration (FDA) found it to be in compliance with current good manufacturing practices (cGMP).
The successful inspection forms part of the company’s PharmaChoices@Jungbunzlauer strategy, which aims to strengthen its presence in the pharma sector, in the US and other markets.
Jungbunzlauer produces a range of pharma excipients at the site, including citric acid, tripotassium citrate, trimagnesium citrate, tricalcium citrate and calcium lactate gluconate.